The pharmaceutical company PJSC NVC “Borshchahivsky Chemical and Pharmaceutical Plant” (BCHP) plans to submit four medicines for registration by the end of 2026, develop nine drugs, and conduct bioequivalence studies for two medicines.
According to BHFZ’s disclosure in the National Securities and Stock Market Commission (NSSMC) disclosure system, in 2026, in accordance with the approved Work Plan for expanding the product portfolio, work is planned on 16 drugs in five dosage forms.
Research and development expenses in the first half of the year totaled 6.41 million UAH, which is 13% more than in the same period of 2025.
Currently, the company’s product portfolio consists of approximately 130 items.
BHFZ also reports that during the first half of 2026, the company produced 22.1 million packages of pharmaceuticals with a total value of 1.389 billion UAH.
The average selling price of the drugs was 56.72 UAH per package. Average revenue amounted to 1.201 billion UAH.
In addition, the company reported that total exports amounted to 198.7 million UAH, accounting for 16.5% of total revenue.
According to the company, the main buyers in the first half of 2026 were BADM LLC, OptimaPharm LTD Joint Venture LLC, and Vaksina Healthcare LLC.
During the first six months of 2026, BHFZ exported its products to 14 countries: Azerbaijan, Bosnia and Herzegovina, Armenia, Georgia, Kazakhstan, Latvia, Lithuania, Moldova, Poland, Portugal, Romania, the United States, Uzbekistan, and Croatia.
At the same time, the domestic market accounts for 83.5% of total sales.
According to the company, based on the results for the first six months of 2026, BHFZ ranks sixth in the pharmaceutical market with a figure of 1.119 billion UAH.
As previously reported, BHFZ increased its net profit by 2.96% to 281.788 million UAH in 2025 and boosted pharmaceutical production by 16% to 37.4 million packages, worth 2.481 billion UAH. According to the company, total sales of finished products and goods in 2025 amounted to 43.8 million packages, which is 6.9% more than in 2024.
In addition, the company reported that in 2025, BHFZ exported products worth 307 million UAH, or 13.7% of total sales.
BHFZ forecasts an 18% increase in net sales revenue for 2026 compared to 2025. Annual growth during 2027–2028 is expected to be 13%
Currently, BHFZ is seeking to recover 50.7 million UAH in damages from the Russian Federation for the destruction and damage to property resulting from armed aggression, specifically the destruction and damage to property caused by a missile strike on July 31, 2025.
The amount of direct (actual) damages incurred by the BHFZ as a result of the loss, destruction, or damage to property (fixed assets and inventory according to the lists) in connection with the Russian Federation’s armed aggression (resulting from the explosion and fire on July 31, 2025), is estimated at 50,760,894 thousand UAH, which, at the NBU exchange rate as of the date of the assessment (July 31, 2025), is equivalent to $1,215,358 thousand.
Currently, the shareholders of BHFZ are the pharmaceutical company PJSC “Pharmaceutical Firm “Darnitsa” (Kyiv), which owns 31.8% of BHFZ’s shares; other shareholders include “Beldor Group” (21.26%) and “Lenik Group” (20.32%) .
The ultimate beneficiaries of BHFZ are Gleb Zagoriy, the beneficiary of the pharmaceutical company “Darnitsa,” as well as Yevgen Sova, Tetiana Artemenko, Mykola Bezpalko, and Oleg Goloborodko.
